Vector Order Determines Protection against Pathogenic Simian Immunodeficiency Virus Infection in a Triple-Component Vaccine by Balancing CD4+ and CD8+ T-Cell Responses
暂无分享,去创建一个
M. Krawczak | K. Überla | B. Keele | M. Tenbusch | S. Sopper | U. Sauermann | C. Stahl‐Hennig | M. Bissa | C. Zanotto | A. Radaelli | C. De Giuli Morghen | Nicole Stolte-Leeb | K. Raue
[1] S. Hammer,et al. Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial , 2017, The Journal of infectious diseases.
[2] B. Jensen,et al. Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication , 2017, EBioMedicine.
[3] R. Jackson,et al. Recombinant fowlpox virus vector-based vaccines: expression kinetics, dissemination and safety profile following intranasal delivery , 2017, The Journal of general virology.
[4] H. Ertl. Viral vectors as vaccine carriers. , 2016, Current opinion in virology.
[5] L. Opitz,et al. Pre-infection transcript levels of FAM26F in peripheral blood mononuclear cells inform about overall plasma viral load in acute and post-acute phase after simian immunodeficiency virus infection , 2016, The Journal of general virology.
[6] F. Cavallo,et al. Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity , 2016, Antiviral research.
[7] A. Hill,et al. Viral vectors as vaccine platforms: from immunogenicity to impact. , 2016, Current opinion in immunology.
[8] F. Barré-Sinoussi,et al. Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset , 2016, PLoS pathogens.
[9] M. Thelen,et al. Biased signaling pathways via CXCR3 control the development and function of CD4+ T cell subsets , 2016, Journal of leukocyte biology.
[10] A. Aldovini. Mucosal Vaccination for Prevention of HIV Infection and AIDS. , 2016, Current HIV research.
[11] Yushi Yao,et al. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens , 2016, Molecular therapy. Methods & clinical development.
[12] M. Robert-Guroff,et al. New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design , 2016, Expert review of vaccines.
[13] A. Bolhassani,et al. Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. , 2016, Vaccine.
[14] Bianka Mussil,et al. Increased BST2 expression during simian immunodeficiency virus infection is not a determinant of disease progression in rhesus monkeys , 2015, Retrovirology.
[15] A. Javed,et al. Noncytolytic CD8+ Cell Mediated Antiviral Response Represents a Strong Element in the Immune Response of Simian Immunodeficiency Virus-Infected Long-Term Non-Progressing Rhesus Macaques , 2015, PloS one.
[16] E. Rosenberg,et al. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy , 2015, Journal of Virology.
[17] E. Hunter,et al. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses , 2015, Proceedings of the National Academy of Sciences.
[18] N. Agarwal,et al. Development of PROSTVAC immunotherapy in prostate cancer. , 2015, Future oncology.
[19] H. Schuitemaker,et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys , 2015, Science.
[20] R. Wilkinson,et al. Six host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse model , 2015, BMC Genomics.
[21] Tao Yang,et al. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1 , 2015, Applied Microbiology and Biotechnology.
[22] A. D. De Groot,et al. Preclinical development of HIvax: Human survivin highly immunogenic vaccines , 2015, Human vaccines & immunotherapeutics.
[23] P. E. Van den Steen,et al. CXCR3 ligands in disease and therapy. , 2015, Cytokine & growth factor reviews.
[24] Greg Finak,et al. COMPASS identifies T-cell subsets correlated with clinical outcomes , 2015, Nature Biotechnology.
[25] R. Franconi,et al. A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers , 2015, Journal of Translational Medicine.
[26] Kylie M. Quinn,et al. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. , 2015, The Journal of clinical investigation.
[27] D. Montefiori,et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection , 2015, Proceedings of the National Academy of Sciences.
[28] R. Jackson,et al. Different HIV pox viral vector-based vaccines and adjuvants can induce unique antigen presenting cells that modulate CD8 T cell avidity. , 2014, Virology.
[29] C. Hioe,et al. Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection. , 2014, AIDS research and human retroviruses.
[30] R. Gallo,et al. Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development , 2014, Proceedings of the National Academy of Sciences.
[31] Jeffrey M. Weiss,et al. Multiple Low-Dose Challenges in a Rhesus Macaque AIDS Vaccine Trial Result in an Evolving Host Response That Affects Protective Outcome , 2014, Clinical and Vaccine Immunology.
[32] D. Barouch,et al. Late Endosomal Trafficking of Alternative Serotype Adenovirus Vaccine Vectors Augments Antiviral Innate Immunity , 2014, Journal of Virology.
[33] H. Erb,et al. Lack of Evidence That Avian Oncogenic Viruses Are Infectious for Humans: A Review , 2014, Avian diseases.
[34] Eric Hunter,et al. Immune Activation with HIV Vaccines , 2014, Science.
[35] K. Überla,et al. Novel Vaccine Regimen Elicits Strong Airway Immune Responses and Control of Respiratory Syncytial Virus in Nonhuman Primates , 2014, Journal of Virology.
[36] C. Tremblay,et al. Transcriptional profiling reveals molecular signatures associated with HIV permissiveness in Th1Th17 cells and identifies Peroxisome Proliferator-Activated Receptor Gamma as an intrinsic negative regulator of viral replication , 2013, Retrovirology.
[37] Mario Roederer,et al. Immunological and Virological Mechanisms of Vaccine-Mediated Protection Against SIV and HIV , 2013, Nature.
[38] D. Montefiori,et al. Resistance to Infection, Early and Persistent Suppression of Simian Immunodeficiency Virus SIVmac251 Viremia, and Significant Reduction of Tissue Viral Burden after Mucosal Vaccination in Female Rhesus Macaques , 2013, Journal of Virology.
[39] J. Berzofsky,et al. Nonhuman Primate Models for HIV/AIDS Vaccine Development , 2013, Current protocols in immunology.
[40] J. Arthos,et al. Preferential HIV Infection of CCR6+ Th17 Cells Is Associated with Higher Levels of Virus Receptor Expression and Lack of CCR5 Ligands , 2013, Journal of Virology.
[41] Christopher J. Miller,et al. Comparative Characterization of Transfection- and Infection-Derived Simian Immunodeficiency Virus Challenge Stocks for In Vivo Nonhuman Primate Studies , 2013, Journal of Virology.
[42] K. Überla,et al. Risk of Immunodeficiency Virus Infection May Increase with Vaccine-Induced Immune Response , 2012, Journal of Virology.
[43] D. Barouch,et al. Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys , 2012, Journal of Virology.
[44] K. Überla,et al. Immunogenicity of DNA Vaccines Encoding Simian Immunodeficiency Virus Antigen Targeted to Dendritic Cells in Rhesus Macaques , 2012, PloS one.
[45] Jerome H. Kim,et al. Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand , 2011, PloS one.
[46] J. Shiver,et al. Low-Dose Penile SIVmac251 Exposure of Rhesus Macaques Infected with Adenovirus Type 5 (Ad5) and Then Immunized with a Replication-Defective Ad5-Based SIV gag/pol/nef Vaccine Recapitulates the Results of the Phase IIb Step Trial of a Similar HIV-1 Vaccine , 2011, Journal of Virology.
[47] M. Bissa,et al. Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein , 2011, Journal of Translational Medicine.
[48] S. Antimisiaris,et al. Topical nonnucleoside reverse transcriptase inhibitor MC 1220 partially prevents vaginal RT-SHIV infection of macaques. , 2011, AIDS research and human retroviruses.
[49] J. Kublin,et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. , 2011, The Lancet. Infectious diseases.
[50] K. Mätz-Rensing,et al. Definition of leukocyte subsets in primate central nervous system by polychromatic flow cytometry , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[51] S. Sopper,et al. Flow cytometric characterization of the lymphocyte composition in a variety of mucosal tissues in healthy rhesus macaques , 2011, Journal of medical primatology.
[52] C. Zanotto,et al. Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison. , 2010, Antiviral research.
[53] C. Zanotto,et al. Canarypox and fowlpox viruses as recombinant vaccine vectors: an ultrastructural comparative analysis , 2010, Archives of Virology.
[54] M. Hudgens,et al. Assessing Vaccine Effects in Repeated Low‐Dose Challenge Experiments , 2009, Biometrics.
[55] R. Steinman,et al. Synthetic Double-Stranded RNAs Are Adjuvants for the Induction of T Helper 1 and Humoral Immune Responses to Human Papillomavirus in Rhesus Macaques , 2009, PLoS pathogens.
[56] K. S. Kim,et al. Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques. , 2009, Virology.
[57] Devan V Mehrotra,et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.
[58] J. Heeney,et al. Better protective effects in rhesus macaques by combining systemic and mucosal application of a dual component vector vaccine after rectal SHIV89.6P challenge compared to systemic vaccination alone. , 2008, Viral immunology.
[59] J. Heeney,et al. Differential CD4 (cid:1) versus CD8 (cid:1) T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates (cid:1) † , 2022 .
[60] R. Steinman,et al. Atraumatic Oral Spray Immunization with Replication-Deficient Viral Vector Vaccines , 2007, Journal of Virology.
[61] Jenny G. Parvani,et al. Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus Vectors , 2007, Journal of Virology.
[62] B. Combadière,et al. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. , 2007, Vaccine.
[63] C. Fernandez,et al. Comparative Efficacy of Subtype AE Simian-Human Immunodeficiency Virus Priming and Boosting Vaccines in Pigtail Macaques , 2006, Journal of Virology.
[64] J. Heeney,et al. Sustained conservation of CD4+ T cells in multiprotein triple modality-immunized rhesus macaques after intrarectal challenge with simian immunodeficiency virus. , 2006, Viral immunology.
[65] A. Ramsay,et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. , 2006, Vaccine.
[66] T. Lehner,et al. Innate and Adaptive Mucosal Immunity in Protection against HIV Infection , 2006, Advances in dental research.
[67] J. Heeney,et al. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model. , 2006, Vaccine.
[68] D. Purcell,et al. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. , 2006, Vaccine.
[69] Arthur M. Krieg,et al. The Toll-Like Receptor 7 (TLR7) Agonist, Imiquimod, and the TLR9 Agonist, CpG ODN, Induce Antiviral Cytokines and Chemokines but Do Not Prevent Vaginal Transmission of Simian Immunodeficiency Virus When Applied Intravaginally to Rhesus Macaques , 2005, Journal of Virology.
[70] D. Weiner,et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. , 2005, AIDS research and human retroviruses.
[71] S. Kent,et al. Phenotypic and kinetic analysis of effective simian-human immunodeficiency virus-specific T cell responses in DNA--and fowlpox virus-vaccinated macaques. , 2005, Virology.
[72] J. Reece,et al. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. , 2005, Vaccine.
[73] K. Überla,et al. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses , 2004, The journal of gene medicine.
[74] David Montefiori,et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[75] J. Heeney,et al. Single-cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live-attenuated SIV vaccines. , 2003, Virology.
[76] D. Venzon,et al. Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251. , 2003, Virology.
[77] E. Vicenzi,et al. Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV. , 2003, Vaccine.
[78] M. Krawczak,et al. MHC Class I Alleles Influence Set-Point Viral Load and Survival Time in Simian Immunodeficiency Virus-Infected Rhesus Monkeys1 , 2002, The Journal of Immunology.
[79] P. Ogra,et al. Vaccination Strategies for Mucosal Immune Responses , 2001, Clinical Microbiology Reviews.
[80] D. Montefiori,et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations , 1999, Nature Medicine.
[81] P. Roques,et al. Selective quasispecies transmission after systemic or mucosal exposure of macaques to simian immunodeficiency virus. , 1998, Virology.
[82] Yufei Wang,et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques , 1996, Nature Medicine.
[83] L. Gritz,et al. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. , 1991, AIDS research and human retroviruses.
[84] R. Alon,et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. , 2014, The Journal of clinical investigation.
[85] M. Platzer,et al. Mhc class I haplotypes associated with survival time in simian immunodeficiency virus (SIV)-infected rhesus macaques , 2008, Genes and Immunity.
[86] D. Venzon,et al. Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques. , 2004, Vaccine.
[87] D. Pinna,et al. Evaluation in rabbits of different anti-SHIV vaccine strategies based on DNA/fowlpox priming and virus-like particle boosting. , 2003, FEMS immunology and medical microbiology.